Core Viewpoint - Company intends to acquire a group of assets from Future Pharmaceuticals for a cash consideration of up to 480 million yuan, which includes both marketed and in-development products related to multi-trace element injection solutions, enhancing its product pipeline and aligning with its health management strategy [1][2] Group 1 - The acquisition includes marketed products "Multi-trace Element Injection (I)" and "Multi-trace Element Injection (II)", as well as the in-development "Multi-trace Element Injection (III)" [1] - The transaction is expected to constitute a significant asset restructuring as per the regulations, and it will not involve share issuance or result in a change of control [1] - The acquisition aligns with the company's strategy to enhance its product matrix for "all-age health management" and optimize its product layout in "anti-infection, chronic disease, and nutritional support" [1] Group 2 - The asset group includes a well-established national sales channel and academic promotion system, which will help the company expand new sales channels for its products [2] - The existing sales network and academic promotion system are expected to significantly facilitate market access and coverage for the company's pediatric anti-influenza drugs [2]

Core Viewpoint - The company, Nanxin Pharmaceutical (688189.SH), has signed a purchase intention agreement to acquire a group of assets from Future Medicine for a cash consideration of up to 480 million yuan, which includes both marketed and in-development products related to multi-trace element injection solutions [1][2] Group 1 - The acquisition will include the marketed products "Multi-trace Element Injection (I)" and "Multi-trace Element Injection (II)", as well as the in-development "Multi-trace Element Injection (III)", along with associated R&D and production technical materials, trademarks, patents, customer data, and regulatory approvals [1] - This transaction is expected to constitute a significant asset restructuring as defined by the regulations governing listed companies, and it will not involve the issuance of new shares or result in a change of control for the company [1] - The acquisition aligns with the company's strategy to enhance its product pipeline and optimize its product layout in the "anti-infection - chronic disease - nutritional support" categories, supporting its broader "healthcare" development strategy [1] Group 2 - The asset group includes a well-established national sales channel and academic promotion system, which will help the company expand new sales channels for its products and significantly enhance market access and coverage for its pediatric anti-influenza medications [2]

Group 1 - Nanjing Pharmaceutical plans to acquire a significant asset group from Future Medicine, which is expected to constitute a major asset restructuring [1] - The acquisition includes both listed products and in-development products related to multiple trace element injection solutions, along with associated intellectual property and market channels [1] Group 2 - Cambrian Technology reported a revenue of approximately 2.88 billion yuan for the first half of 2025, a year-on-year increase of 4,347.82%, and a net profit of approximately 1.04 billion yuan, reversing a loss from the previous year [2] - Northern Rare Earth achieved a revenue of approximately 18.87 billion yuan, up 45.24% year-on-year, with a net profit of approximately 931 million yuan, a significant increase of 1,951.52% [2] - Light Media reported a revenue of 3.24 billion yuan, a 143% increase year-on-year, and a net profit of approximately 2.23 billion yuan, up 371.55% [2] - Victory Technology's revenue reached approximately 9.03 billion yuan, an 86% increase year-on-year, with a net profit of approximately 2.14 billion yuan, up 366.89% [2] Group 3 - Zhongji Xuchuang reported a revenue of approximately 14.79 billion yuan for the first half of 2025, a 36.95% increase year-on-year, and a net profit of approximately 3.99 billion yuan, up 69.4% [3] - Fosun Pharma's revenue for the first half of 2025 was approximately 19.51 billion yuan, with a net profit of approximately 1.70 billion yuan, a 38.96% increase year-on-year [3] - CNOOC Services reported a revenue of approximately 23.32 billion yuan, a 3.5% increase year-on-year, and a net profit of approximately 1.96 billion yuan, up 23.3% [3] - Qingdao Beer achieved a revenue of approximately 20.49 billion yuan, a 2.11% increase year-on-year, with a net profit of approximately 3.90 billion yuan, up 7.21% [3] Group 4 - Shiyun Circuit plans to invest approximately 1.5 billion yuan in a new PCB manufacturing base project to enhance production capacity for embedded chip PCBs and advanced HDI products, with a designed capacity of 660,000 square meters per year [4] Group 5 - Perfect World reported a revenue of approximately 3.69 billion yuan for the first half of 2025, a 33.74% increase year-on-year, and a net profit of approximately 503 million yuan, reversing a loss from the previous year [6]

格隆汇8月26日丨南新制药(688189.SH)公布，2025年8月26日，公司与未来医药签署了《收购意向协 议》。公司拟以现金不超过4.8亿元收购未来医药持有的标的资产组，包括已上市标的品种"多种微量元 素注射液（Ⅰ）"、"多种微量元素注射液（Ⅱ）"和在研标的品种"多种微量元素注射液（Ⅲ）"，以及 与标的品种相关的研发和生产技术资料、商标、专利、客户资料（市场渠道）、批文等资产完整的所有 权及知识产权。 本次交易尚处于筹划阶段，具体交易方案将由相关各方根据审计及评估结果进一步协商谈判以及履行必 要的决策和审批程序后，另行签订正式的交易协议予以确定。因此，本次交易尚存在不确定性。 ...

格隆汇8月26日丨南新制药(688189.SH)公布，公司及控股子公司深圳高芯思通科技有限公司（以下简 称"高芯思通"）拟进行办公布局优化调整，双方拟与深圳湾科技发展有限公司重新签署《房屋租赁合 同》，向深圳湾科技发展有限公司租赁深圳市南山区深圳湾创新科技中心一期2栋A座（研发）20层部 分、21层整层、23层整层，租赁房屋建筑面积共计6,403.34㎡，用于研发办公，租金总额约为2,701.99万 元（含税，不含水电费、物业管理费等其他费用）。双方于2024年12月签署的《房屋租赁合同》及补充 协议将于2025年8月31日终止。 ...

格隆汇8月26日丨南新制药(688189.SH)公布，公司及控股子公司深圳高芯思通科技有限公司（以下简 称"高芯思通"）拟进行办公布局优化调整，双方拟与深圳湾科技发展有限公司重新签署《房屋租赁合 同》，向深圳湾科技发展有限公司租赁深圳市南山区深圳湾创新科技中心一期2栋A座（研发）20层部 分、21层整层、23层整层，租赁房屋建筑面积共计6,403.34㎡，用于研发办公，租金总额约为2,701.99万 元（含税，不含水电费、物业管理费等其他费用）。双方于2024年12月签署的《房屋租赁合同》及补充 协议将于2025年8月31日终止。 （原标题：南新制药(688189.SH)及子公司拟重新签署租赁合同） ...

Core Viewpoint - Nanjing Pharmaceutical plans to acquire a set of assets from Future Medicine for a total consideration of up to 480 million yuan, which includes both listed and in-development products related to multi-trace element injection solutions, enhancing its product pipeline and aligning with its health management strategy [1] Group 1: Acquisition Details - The acquisition involves cash payment for assets including "Multi-trace Element Injection (I)", "Multi-trace Element Injection (II)", and the in-development "Multi-trace Element Injection (III)" [1] - The transaction is expected to constitute a significant asset restructuring as defined by the regulations for listed companies [1] - The overall valuation for the transaction is projected to be no more than 480 million yuan [1] Group 2: Strategic Implications - This acquisition will enrich the company's product pipeline and improve its product matrix for "whole-age health management" [1] - It aims to optimize the company's layout in the "anti-infection - chronic disease - nutritional support" sectors [1] - The move aligns with the company's broader "big health" development strategy [1]

Group 1 - The State Council emphasizes increasing financial and fiscal support for the artificial intelligence (AI) sector, aiming for over 70% penetration of new intelligent terminals and agents by 2027 [2][3] - By 2030, AI is expected to significantly contribute to high-quality economic development, with over 90% penetration of new intelligent applications [2] - The government plans to enhance the legal and regulatory framework for AI, including risk management and investment exit mechanisms [2][4] Group 2 - The National Development and Reform Commission (NDRC) will coordinate efforts to implement the AI action plan, ensuring local adaptation and avoiding superficial compliance [4] - The NDRC aims to foster a complete AI application service chain and promote the development of intelligent native technologies and services [4] - The NDRC will also support open-source ecosystem development to enhance international influence [4] Group 3 - The National Energy Administration acknowledges that the rapid growth of electric vehicle and AI sectors is driving increased electricity demand, which is reshaping energy consumption patterns [5][6] - Data indicates a 34.3% year-on-year increase in electricity consumption for new energy vehicle manufacturing in 2024, and a 20.5% increase for internet and related services [5][6] Group 4 - The new generation of the Chinese operating system, Galaxy Kirin V11, has been officially released, featuring significant improvements in architecture, security, and ecosystem compatibility [6] - Galaxy Kirin has achieved over 16 million deployments and is compatible with major domestic CPUs and GPUs, supporting various national projects [6] Group 5 - ByteDance has raised its option price to $200.41 per share, marking a significant increase from $189.9 earlier this year, reflecting a fivefold increase since 2019 [6] Group 6 - Aliyun's Baolian has announced a price reduction for certain model context caching, lowering the cost from 40% to 20% of the input token price when cache hits occur [7] Group 7 - Union Medical has received a medical device registration certificate for China's first photon counting spectral CT, marking a significant advancement in medical technology [8] - Nanjing New Pharmaceutical plans to acquire assets from Future Medicine for up to 480 million yuan, which is expected to constitute a major asset restructuring [9] - Biyimi plans to acquire 100% of Shanghai Xingan Semiconductor for 295 million yuan to enhance its core business and technology capabilities [10]

证券代码：688189 证券简称：南新制药 公告编号：2025-031 湖南南新制药股份有限公司 关于筹划重大资产重组暨签署《收购意向协议》的提示性公告 6、公司预计将于 6 个月内披露本次交易相关的预案或正式方案。 一、本次交易概述 2025 年 8 月 26 日，公司与未来医药签署了《收购意向协议》。公司拟以现 金不超过 4.8 亿元收购未来医药持有的标的资产组，包括已上市标的品种"多种 微量元素注射液（Ⅰ）"、"多种微量元素注射液（Ⅱ）"和在研标的品种"多种微 量元素注射液（Ⅲ）"，以及与标的品种相关的研发和生产技术资料、商标、专利、 客户资料（市场渠道）、批文等资产完整的所有权及知识产权。 本次交易尚处于筹划阶段，具体交易方案将由相关各方根据审计及评估结果 进一步协商谈判以及履行必要的决策和审批程序后，另行签订正式的交易协议予 以确定。因此，本次交易尚存在不确定性。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、2025 年 8 月 26 日，湖南南新制药股份有限公司（以下简称"公司"）与 西 ...

（原标题：南新制药8月18日龙虎榜数据） 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 资金流向方面，该股今日全天主力资金净流入1.02亿元。 另据统计，近半年该股累计上榜龙虎榜5次，上榜次日股价平均涨12.19%，上榜后5日平均涨10.25%。 （数据宝） 南新制药8月18日龙虎榜 | 买入营业部名称 | 买入 | | --- | --- | | | 金额(万元) | | 国泰海通证券股份有限公司总部 | 3959.00 | | 机构专用 | 3015.11 | | 瑞银证券有限责任公司上海花园石桥路证券营业部 | 1661.88 | | 高盛(中国)证券有限责任公司上海浦东新区世纪大道证券营业部 | 1495.25 | | 华鑫证券有限责任公司上海宛平南路证券营业部 | 980.83 | | 卖出营业部名称 | 卖出 | | | 金额(万元) | | 中信证券股份有限公司上海分公司 | 1966.06 | | 国泰海通证券股份有限公司总部 | 1251.36 | | 高盛(中国)证券有限责任公司上海浦东新区世纪大道证券营业部 | 1235.57 | | 瑞银证券有限责任公司上海花园石桥路证 ...